MedTrace Logo

68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

NCT05673031 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-01-05

No results posted yet for this study

Summary

To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]

Conditions

  • Neuroendocrine Tumors (NET)

Interventions

DIAGNOSTIC_TEST

68Ga-HA-DOTATATE PET/CT imaging

Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients. * After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans. * The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results.

Sponsors & Collaborators

  • Alberta Health services

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2027-01-01
Completion
2027-01-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05673031 on ClinicalTrials.gov